BBIO BridgeBio Pharma, Inc.

NASDAQ
$65.57

BridgeBio Pharma, Inc. (BBIO) is expected to report earnings on November 2, 2026, after the market close. The consensus earnings estimate is a loss of $0.67 per share, and the stock has had a Post-Earnings Announcement Drift (PEAD) of -24.7% since its last earnings release on August 10, 2026.

BridgeBio Pharma Missed Consensus Estimates
Monday, August 10, 2026 · 4:01 PM ET
Earnings Date
3rd Quarter, Sep 2026
Nov 2
Monday · 4:00 PM ET
Earnings Whisper
-
vs ($0.67)
Rev est $269.13M
Volatility
Enter your expectations below to reveal the current volatility.
Trend Analysis
Expectation
Earnings
Price action
Signals
Score
Sentiment
Grade
Life Cycle
Call Analysis
Earnings-AVWAP $74.94

Sign in or subscribe to unlock sentiment, short interest, and technical indicators.

About BridgeBio Pharma, Inc.

BridgeBio Pharma, Inc. is a new type of biopharmaceutical company founded to discover, create, test, and deliver transformative medicines to treat patients who suffer from genetic diseases.

Sector

Healthcare

Industry

Biotechnology

Held By 4 ETFs, by dollar flow

Charts powered in part by Lightweight Charts™ by TradingView.